Clinical trials: Depressive; Episode, Major
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.
- Trial name
- NCT01001559
- Testing
- L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pamlab, Inc.
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- ORION (NCT00252356)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 468 people
- Sponsor
- Sanofi
Major Depressive Episode Associated With Bipolar II Disorder
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder.
- Trial name
- NCT06429722
- Testing
- NMRA-335140 80 mg
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neumora Therapeutics, Inc.
Bipolar II Disorder, Most Recent Episode Major Depressive
Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression
Depression is a medical condition characterized by feeling sad even when good things happen, having low energy and motivation, and sometimes even experiencing suicidal thoughts.
- Trial name
- NCT00475137
- Testing
- Lamotrigine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University of British Columbia
Major Depressive Disorder, Single Episode, Unspecified
Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents
In this study, we test whether a two-week 8-session neutral attention bias modification (ABM) training and a two-week 4-session positive ABM could reduce depressive symptoms relative to placebo controls in adolescents with major…
- Trial name
- NCT02078258
- Testing
- ABMT
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Hunan Normal University
Bipolar Affective Disorder
Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.
Initially, observational studies suggested a possible effect of Lacosamide on depressive and anxious symptoms in individuals with epilepsy, and later, an open-label study demonstrated the efficacy of lacosamide in improving…
- Trial name
- NCT07412132
- Testing
- Lacosamide
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo
Major Depressive Episode
Ketamine as an Anaesthetic Agent in Electroconvulsive Therapy (ECT)
Research into the mechanisms underlying memory impairment in ECT suggests that its development may be prevented by the administration of certain medications at the time of ECT treatment.
- Trial name
- NCT00680433
- Testing
- Ketamine, Saline
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Northside Clinic, Australia
Treatment Resistant Depression, Electroconvulsive Therapy
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as…
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine
- Trial name
- ELEKT-D (NCT03113968)
- Testing
- electroconvulsive therapy (ECT), Ketamine
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Bo Hu
Major Depression, Depressive Episodes
Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health
The purpose of this randomized multiple-site clinical study is to determine whether a revised CATCH-IT (Internet-based depression prevention program) is more effective than a general health education Internet intervention (Health…
- Trial name
- CATCH-IT (NCT01893749)
- Testing
- CATCH-IT
- Where
- 7 sites in United States
- Volunteers
- 1,142 people, healthy volunteers welcome
- Sponsor
- Benjamin Van Voorhees, MD, MPH
Depression
Treating Depression With Transcranial Direct Current Stimulation (tDCS)
The purpose of this study is to see if transcranial direct current stimulation may improve the symptoms of depression.
- Trial name
- NCT00481988
- Testing
- transcranial direct current stimulation, iomed phoresor transcranial direct current stimulation
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York State Psychiatric Institute
Psychotic Disorders, Autism Spectrum Disorder
EEG Microstates Across At-Risk Mental States
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6).
- Conditions
- Psychotic Disorders, Autism Spectrum Disorder, Major Depressive Disorder, Schizophrenia
- Trial name
- DEMETER (NCT06045897)
- Testing
- EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis
- Where
- France
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Major Depressive Disorder
Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants
GLYX-13 is a NMDA receptor glycine site partial agonist being studied in subjects with major depressive disorder (depression) who have responded inadequately to another antidepressant drug during the current episode.
- Trial name
- NCT01684163
- Testing
- GLYX-13 5 mg/kg, GLYX-13 10 mg/kg
- Where
- 26 sites in United States
- Volunteers
- 369 people
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
Bipolar Depression
Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
The study will evaluate the efficacy and safety of ITI-007 (Lumateperone) in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode. The study will be conducted in two parts, Part A and Part B.
- Trial name
- NCT02600494
- Testing
- ITI-007 (Lumateperone)
- Where
- 55 sites in United States
- Volunteers
- 554 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Major Depressive Disorder
A Study of Aripiprazole in Patients With Major Depressive Disorder
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy…
- Trial name
- NCT00105196
- Testing
- Aripiprazole+ ADT
- Where
- 34 sites in United States
- Volunteers
- 349 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autism Spectrum Disorder, Depression
Feasibility and Efficacy of rTMS in Depression in Patients With Autism Spectrum Disorder (ASD)
Depression is a common complication of Autism Spectrum Disorder (ASD): it is four times more prevalent in people with ASD than in the general population.
- Conditions
- Autism Spectrum Disorder, Depression, Major Depressive Episode (MDE)
- Trial name
- DEPASS'R (NCT07258914)
- Testing
- rTMS, rTMS treatment with intermittent Theta Burst (ITBS)
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Hospital Center Guillaume Régnier
Major Depressive Disorder
Switching From SSRI to Desvenlafaxine on Cognitive Functioning
Given the importance of cognitive function on depressed patients' treatment outcome and return to premorbid functioning, the effect of antidepressant drugs on cognition has become of primary concern.
- Trial name
- NCT03432221
- Testing
- Desvenlafaxine
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- PHOENIX (NCT00252330)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 476 people
- Sponsor
- Sanofi